• Epidemiology and risk factors
• 30 min
  1. Epidemiology of COPD

  • Dr. David Mannino
• 36 min
  2. COPD in never smokers

  • Dr. Sundeep Salvi
• 43 min
  3. Genetics of chronic obstructive pulmonary disease (COPD)

  • Prof. Martin Tobin
• Phenotypes of COPD
• 44 min
  4. COPD and asthma: similarities and differences

  • Prof. Peter Barnes
• Pathophysiology and mechanisms of COPD
• 43 min
  5. The pathology of chronic obstructive pulmonary disease

  • Prof. James Hogg
• 63 min
  6. The continuum of COPD: a physiological perspective

  • Prof. Denis O'Donnell
• 47 min
  7. Inflammatory and immune mechanisms in COPD

  • Prof. Peter Barnes
• 44 min
  8. Mechanisms of COPD exacerbations and relation to exacerbation therapy

  • Prof. Wisia Wedzicha
• 39 min
  9. Protease-antiprotease balance

  • Prof. Robert Stockley
• Therapy and management
• 42 min
  10. Updates in chronic obstructive pulmonary disease (COPD)

  • Dr. Omar S. Usmani
• 45 min
  11. Long-acting bronchodilators in COPD

  • Prof. Bart Celli
• 54 min
  12. Treatment of COPD exacerbations

  • Prof. Antonio Anzueto
• 25 min
  13. Pulmonary rehabilitation: history, promise and problems

  • Prof. Richard Casaburi
• 29 min
  14. Lung volume reduction: advances in COPD

  • Dr. Nick Hopkinson
• 35 min
  15. New pharmacological therapies for COPD

  • Prof. Peter Barnes
• 32 min
  16. The Salford lung study in COPD

  • Dr. Dave Leather
• COPD case studies
• 11 min
  17. COPD treatment case I: COPD with “bronchitis attacks”

  • Dr. Janwillem Kocks
• 13 min
  18. COPD treatment case II: COPD with asthma as child

  • Dr. Janwillem Kocks
• 12 min
  19. COPD treatment case III: COPD with pre-diabetes

  • Dr. Janwillem Kocks
• 48 min
  20. Tailoring care for advanced COPD

  • Prof. Wissam Chatila
• Archived Lectures *These may not cover the latest advances in the field
• 59 min
  21. Alpha-1 antitrypsin deficiency: state of the art

  • Dr. Jamie Stoller
• 34 min
  22. Oxidative stress in COPD

  • Prof. William MacNee
• 24 min
  23. Managing co-morbidity in COPD

  • Dr. John Hurst
• 40 min
  24. Clinical phenotypes of COPD

  • Prof. Jørgen Vestbo
• 27 min
  25. Pulmonary rehabilitation: focusing on rehabilitative exercise

  • Prof. Richard Casaburi
• 36 min
  26. Genetics of COPD

  • Prof. Ian Hall

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Overview
3. Systemic consequences and co-morbidity
4. What is COPD?
5. What is a co-morbidity?
6. Comorbid diagnoses and symptoms in COPD
7. Co-morbidity in COPD (1)
8. More common than...
9. Some common comorbidities in COPD patients
10. Lung cancer, COPD and smoking
11. Clinical importance of assessing co-morbidity
12. Why co-morbidity is important
13. COPD affects co-morbidity
14. Co-morbidity affects COPD
15. Exacerbation susceptibility
16. GORD in COPD
17. COPD & co-morbidity: a reciprocal relationship
18. Mechanisms of co-morbidity in COPD
19. Co-morbidity in COPD (2)
20. COP(D) and ageing
21. Co-morbidity in COPD (3)
22. Mechanisms
23. Questions
24. Systemic inflammation and vascular risk
25. RA and vascular risk
26. COPD: systemic inflammation
27. Systemic and airway inflammation in COPD
28. Systemic inflammation at exacerbation of COPD
29. COPD and MI risk (1)
30. COPD and MI risk (2)
31. Management of co-morbidity in COPD
32. Principles
33. UK NICE guidance
34. GOLD: COPD and co-morbidities
35. Conclusion
36. Thank you

Topics Covered

• COPD is associated with multiple systemic co-morbidities including increased cardiovascular risk, osteoporosis, metabolic disturbance, and skeletal muscle dysfunction
• The importance of assessing co-morbidity in COPD
• The mechanisms of interaction between COPD and co-morbidities
• How to manage co-morbidity in a patient with COPD

Links

Series:

• Advances in Chronic Obstructive Pulmonary Disease (COPD)

Categories:

• Clinical Practice

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on August 1, 2012
• Archived on February 25, 2021

Financial Disclosures

• Dr. John Hurst has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.